ECSP21044843A - Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina - Google Patents

Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina

Info

Publication number
ECSP21044843A
ECSP21044843A ECSENADI202144843A ECDI202144843A ECSP21044843A EC SP21044843 A ECSP21044843 A EC SP21044843A EC SENADI202144843 A ECSENADI202144843 A EC SENADI202144843A EC DI202144843 A ECDI202144843 A EC DI202144843A EC SP21044843 A ECSP21044843 A EC SP21044843A
Authority
EC
Ecuador
Prior art keywords
imidazopyridazine
inhibitors
compounds
receptor kinase
activin receptor
Prior art date
Application number
ECSENADI202144843A
Other languages
English (en)
Inventor
Wenqing Yao
Jeremy Roach
Liangxing Wu
Chunhong He
Jun Pan
Song Mei
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of ECSP21044843A publication Critical patent/ECSP21044843A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos de Fórmula (I), métodos para usar los compuestos para inhibir la actividad de ALK2 y composiciones farmacéuticas que comprenden tales compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de ALK2, como el cáncer.
ECSENADI202144843A 2018-12-20 2021-06-21 Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina ECSP21044843A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862782994P 2018-12-20 2018-12-20
US201962935891P 2019-11-15 2019-11-15

Publications (1)

Publication Number Publication Date
ECSP21044843A true ECSP21044843A (es) 2021-09-30

Family

ID=69467674

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202144843A ECSP21044843A (es) 2018-12-20 2021-06-21 Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina

Country Status (20)

Country Link
US (2) US11459329B2 (es)
EP (1) EP3898627A1 (es)
JP (2) JP7414827B2 (es)
KR (1) KR20210116488A (es)
CN (1) CN114787160A (es)
AU (1) AU2019401649A1 (es)
BR (1) BR112021011948A2 (es)
CA (1) CA3124088A1 (es)
CL (1) CL2021001656A1 (es)
CO (1) CO2021008117A2 (es)
CR (1) CR20210336A (es)
EC (1) ECSP21044843A (es)
IL (1) IL284139A (es)
MA (1) MA54551A (es)
MX (1) MX2021007426A (es)
PE (1) PE20220277A1 (es)
PH (1) PH12021551446A1 (es)
SG (1) SG11202106582YA (es)
TW (1) TW202039502A (es)
WO (1) WO2020132197A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019401649A1 (en) * 2018-12-20 2021-07-08 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
TW202214660A (zh) 2020-06-12 2022-04-16 美商英塞特公司 咪唑并嗒嗪化合物及其用途
WO2023066204A1 (zh) * 2021-10-18 2023-04-27 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
PT1812440E (pt) 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
ES2689444T3 (es) * 2006-11-22 2018-11-14 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
ATE522249T1 (de) 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
ES2393430T3 (es) * 2007-10-17 2012-12-21 Novartis Ag Derivados de imidazo[1,2-A]-piridina útiles como inhibidores de ALK
EP2453882A1 (en) 2009-07-14 2012-05-23 Beth Israel Deaconess Medical Center, Inc. Methods of increasing liver proliferation
WO2012013713A2 (en) * 2010-07-28 2012-02-02 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-b]pyridazines
KR102092988B1 (ko) 2012-09-28 2020-03-25 벤더르빌트 유니버시티 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들
MX2015005375A (es) 2012-11-07 2015-07-21 Hoffmann La Roche Compuestos de triazolo.
WO2014160203A2 (en) * 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
EP3390361B1 (en) 2015-12-17 2022-03-16 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
SG11201805300QA (en) 2015-12-22 2018-07-30 Incyte Corp Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3028685A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3033755A1 (en) 2016-08-17 2018-03-01 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2018053126A1 (en) * 2016-09-14 2018-03-22 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
HRP20221216T1 (hr) 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
ES2934230T3 (es) 2016-12-22 2023-02-20 Incyte Corp Derivados de benzooxazol como inmunomoduladores
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US20200054643A1 (en) 2017-01-18 2020-02-20 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
WO2018165569A1 (en) * 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
PE20200008A1 (es) 2017-03-30 2020-01-06 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1
AU2019401649A1 (en) * 2018-12-20 2021-07-08 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Also Published As

Publication number Publication date
US20200199131A1 (en) 2020-06-25
US11459329B2 (en) 2022-10-04
JP2024045155A (ja) 2024-04-02
AU2019401649A1 (en) 2021-07-08
CL2021001656A1 (es) 2021-12-17
US20220315595A1 (en) 2022-10-06
JP7414827B2 (ja) 2024-01-16
TW202039502A (zh) 2020-11-01
MA54551A (fr) 2021-10-27
SG11202106582YA (en) 2021-07-29
PH12021551446A1 (en) 2021-12-06
BR112021011948A2 (pt) 2021-09-08
CA3124088A1 (en) 2020-06-25
MX2021007426A (es) 2021-09-08
EP3898627A1 (en) 2021-10-27
CR20210336A (es) 2021-12-06
CO2021008117A2 (es) 2021-09-20
PE20220277A1 (es) 2022-02-25
WO2020132197A1 (en) 2020-06-25
CN114787160A (zh) 2022-07-22
KR20210116488A (ko) 2021-09-27
IL284139A (en) 2021-08-31
JP2022514650A (ja) 2022-02-14

Similar Documents

Publication Publication Date Title
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP20060827A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP21044843A (es) Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
ECSP18014798A (es) Inhibidores de ezh2
CL2022000457A1 (es) Triazolopirimidinas como inhibidores de a2a/a2b.
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
AR117459A1 (es) Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos
CO2022017969A2 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
EA202191738A1 (ru) Соединения имидазопиридазина и имидазопиридина и их применение
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP15021681A (es) Derivados tricíclicos fusionados de tiofeno como inhibidores de jak